You are here

  • Home
  • Archive
  • Volume 81, Issue 6
  • Persistence and effectiveness of the IL-12/23 pathway inhibitor ustekinumab or tumour necrosis factor inhibitor treatment in patients with psoriatic arthritis: 1-year results from the real-world PsABio Study

Citation Tools

Article menu
Psoriatic arthritis
Persistence and effectiveness of the IL-12/23 pathway inhibitor ustekinumab or tumour necrosis factor inhibitor treatment in patients with psoriatic arthritis: 1-year results from the real-world PsABio Study

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Gossec L, Siebert S, Bergmans P, et al
Persistence and effectiveness of the IL-12/23 pathway inhibitor ustekinumab or tumour necrosis factor inhibitor treatment in patients with psoriatic arthritis: 1-year results from the real-world PsABio Study
Annals of the Rheumatic Diseases 2022;81:823-830.